We report two cases of severe leg ulcerations in patients being treated with thalidomide for graft-versus-host disease following bone marrow transplantation. Local wound care and debridement were attempted, but one patient required skin grafting to ensure healing. We propose that this complication may be due to the antiangiogenic properties of thalidomide and urge careful attention to skin breakdown in patients being treated with this compound. Bone Marrow Transplantation (2001) 27, 229-230. Keywords: thalidomide; skin; ulceration; transplant; GVHD
Patient 1
A 47-year-old man with progressive B cell chronic lymphocytic leukemia (CLL) originally treated with fludarabine, prednisone, danozol, leukeran, cytoxan, vincristine and dexamethasone underwent an allogeneic bone marrow transplant with busulfan/cytoxan conditioning in February 1996. On day 28 he developed total body erythema with some skin desquamation which resolved following treatment with methylprednisolone and cyclosporine. On day 73 staphylococcal A immunopheresis was utilized to treat severe immune thrombocytopenic purpura due to an auto-antibody. By day 98 this had resolved following six aphereses. His skin was still dry at this time, but no longer flaking. By day 400 his CLL was in full remission. His skin was lichenified in areas of his torso but no sclerodermatous changes were noted. His immunosuppressives were stopped on day 500. On day 510 he was doing well with some thickened skin and scaling over his hands and knuckles. Two weeks after stopping the immunosuppressives, his skin began to desquamate again and his calves and shins were painful. By day 593 he had only minimal skin flakiness with prednisone 20 mg/day and etritinate 25 mg/day. Around day 810 he began complaining about pain in both shins. On day 1034 both shins began to ooze serous material. On day 1065 he started FK506 10 mg/day and mycophenolate 2 g/day. After a week of this the right shin was still weeping. The skin breakdown continued for another month, with local wound care and dressing changes. The wounds were up to 3 cm in size. On day 1165 he began thalidomide at 200 mg/day. On day 1179 the thalidomide was increased to 400 mg/day. On day 1184 thalidomide was increased to 600 mg/day. The wounds continued to drain serosanguinous fluid. The wounds continued to drain fluid and were not healing. Thalidomide was decreased to 400 mg/day on day 1305. On day 1328 he was admitted to the hospital for fever and cough, at which time the thalidomide was discontinued. X-rays determined that he had bilateral acinetobacter osteomyelitis in his tibiae, for which he received 8 weeks of vancomycin and imipenem. Two months after stopping thalidomide, his wounds were noted to be filling with granulation tissue and healing. However, pain continued and on day 1430 he was treated with human skin grafts. His wounds at this time were 27 × 10 cm and 26 × 16 cm. These grafts are now healing well, and he was most recently seen on day 1499 with continuously improving ulcerations.
Patient 2
A 39-year-old female with B cell CLL received an allogeneic stem cell transplant following conditioning with cytoxan-total body irradiation in February 1997. Cyclosporine/methotrexate graft-versus-host disease (GVHD) prophylaxis was administered and she was discharged on cyclosporine 500 mg/day. Between day 100 and day 900 she was treated with corticosteroids and mycophenolate for chronic GVHD primarily involving the skin. On day 898, thalidomide was begun at 100 mg/day. The thalidomide was increased to 200 mg/day after 2 weeks of treatment. On day 924, ulcers were noted on the left anterior shin and around both ankles, to which silver sulfadiazine was applied. However, the patient reported significant improvement in her GVHD symptoms and the predni- sone dose was tapered to 40 mg/day and thalidomide was increased to 300 mg/day. By January 2000, the ulcers extended from her knees to her ankles bilaterally and the patient was admitted for intense local wound care. Because of the previous patient's course, thalidomide was switched to mycophenolate despite the apparent improvement of the skin GVHD. With the thalidomide stopped, and intense local wound care, the ulcers regressed and the patient was discharged in an improved state. Unfortunately, she developed acute bronchopneumonia leading to sepsis and expired on day 1114. No organisms were isolated at autopsy. The skin at autopsy showed healing ulcers and granulation tissue.
Discussion
We report two cases of severe anterior tibial skin ulcerations in CLL patients treated with thalidomide for chronic skin GVHD after allogeneic bone marrow transplant.
Thalidomide is theorized to function as a downregulator of graft T cells at the antigen-recognition level. 1 It has been reported to be useful in chronic GVHD in patients who do not respond to other therapies. One series showed benefit in 20% of patients 2 with chronic skin GVHD. It should be noted that 36% discontinued therapy because of side-effects including skin rashes.
Thalidomide has also been shown to have an anti-angiogenic effect. 3 We theorize that this effect, coupled with the extremely thin skin over the anterior tibia, can magnify what would normally be minor trauma into a dangerous necrotic lesion. Local wound care and discontinuation of thalidomide resulted in healing in the second case, while the first required aggressive skin grafting to close the wound. In skin already affected by chronic GVHD, special care should be paid to the anterior tibial region, and immediate care given if the skin shows signs of breakdown. Discontinuation of the thalidomide should be considered, depending on the patient's clinical state.
Only the CLL patients at our institution have suffered this side-effect. Of the five patients we have treated with thalidomide, only these two have shown this effect. It is of interest to note that both of the patients who have undergone allogeneic transplant for CLL at our institution developed severe cutaneous leg ulcers, whereas none of the 127 patients who have undergone allogeneic transplant for other indications developed this complication (P Ͻ 0.0002, Fisher's exact test). It may be that some impairment of angiogenesis related to CLL interacts with thalidomide in such a way as to cause this. This may be borne out by a study of wound healing in guinea pigs which showed that although thalidomide decreased vessel density, it led to increased granulation and improved healing. 4 This might lead one to believe that CLL itself leads to leg ulcerations after allogeneic transplant, but this seems less likely since discontinuation of thalidomide led to improvement in the ulcerations of both of our patients.
